Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results